Search - tctmd.com

Displaying 21 - 40 of 58

Sort: Relevancy | Date

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Industry News

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

August 16, 2019

News Daily News

New TAVR NCD a ‘Missed Opportunity’ to Align SAVR, TAVR Quality

Shelley Wood

June 27, 2019

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

News Conference News TVT 2019

Transcarotid Bests Aortic/Apical for Alternative TAVR Access: TVT Registry

Shelley Wood

June 17, 2019

News Daily News

Similar Mortality, Higher Early Stroke Risks in TAVR for Bicuspid Aortic Stenosis

Michael O'Riordan

June 11, 2019

News Daily News

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Shelley Wood

April 24, 2019

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

News Daily News

Lotus Maintains Good Safety, Efficacy at 2 Years, Though Questions Persist Over Permanent Pacing

Yael L. Maxwell

March 01, 2019

News Daily News

TAVR’s Two-Surgeon Sign-off Rule Must Go, Experts Say

Shelley Wood

July 23, 2018

News Daily News

Hemodynamic Deterioration Post-SAVR: Dysmetabolic Profile, Calcification Could Be Early Warning Signs

Caitlin E. Cox

July 10, 2018

News Conference News SCAI 2018

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

Shelley Wood

April 28, 2018

News Daily News

New Surgical Valve Durability Data Set ‘Critical Benchmark’ for TAVR Devices

Yael L. Maxwell

March 26, 2018

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

News Conference News TCT 2017

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Yael L. Maxwell

November 09, 2017

News Daily News

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

Caitlin E. Cox

September 29, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Daily News

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

L.A. McKeown

August 24, 2016

Advertisement

FDA Expands TAVR Indication to Low-Risk Patients

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

New TAVR NCD a ‘Missed Opportunity’ to Align SAVR, TAVR Quality

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Transcarotid Bests Aortic/Apical for Alternative TAVR Access: TVT Registry

Similar Mortality, Higher Early Stroke Risks in TAVR for Bicuspid Aortic Stenosis

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Lotus Maintains Good Safety, Efficacy at 2 Years, Though Questions Persist Over Permanent Pacing

TAVR’s Two-Surgeon Sign-off Rule Must Go, Experts Say

Hemodynamic Deterioration Post-SAVR: Dysmetabolic Profile, Calcification Could Be Early Warning Signs

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

New Surgical Valve Durability Data Set ‘Critical Benchmark’ for TAVR Devices

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content